Market Research Logo

Contraception - Pipeline Review, H2 2015

Contraception - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Contraception - Pipeline Review, H2 2015’, provides an overview of the Contraception’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Contraception
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Contraception and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Contraception pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Contraception
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Contraception Overview
Therapeutics Development
Pipeline Products for Contraception - Overview
Pipeline Products for Contraception - Comparative Analysis
Contraception - Therapeutics under Development by Companies
Contraception - Therapeutics under Investigation by Universities/Institutes
Contraception - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Contraception - Products under Development by Companies
Contraception - Products under Investigation by Universities/Institutes
Contraception - Companies Involved in Therapeutics Development
Agile Therapeutics, Inc.
Allergan Plc
ANI Pharmaceuticals, Inc.
Antares Pharma, Inc.
Evofem, Inc.
Hydra Biosciences, Inc.
Ligand Pharmaceuticals, Inc.
Orbis Biosciences, Inc.
Pantarhei Bioscience BV
Spermatech AS
Contraception - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(ethinyl estradiol + levonorgestrel) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(nestorone + estradiol acetate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(prasterone + estradiol + progesterone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AG-200 ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AG-200 SP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amphora - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Male Contraception - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EP-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
esterol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etonogestrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EVE-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levonorgestrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LJ-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugates for Contraception - Drug Profile
Product Description
Mechanism of Action
R&D Progress
norethindrone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-003296 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-0101255 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule 1 for Fertility Control - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule 2 for Fertility Control - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Modulate Progesterone Receptor for Fertility Control - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Block CatSper1 Ion Channel for Contraception - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for Contraception - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tanaproget - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Contraception - Recent Pipeline Updates
Contraception - Dormant Projects
Contraception - Dormant Projects
Contraception - Discontinued Products
Contraception - Product Development Milestones
Featured News & Press Releases
Jul 13, 2015: Aquila Solutions,Partners with Evofem to Submit New Drug Application to U.S. FDA for Amphora as a Contraceptive
Jul 06, 2015: Evofem Submits New Drug Application to U.S. FDA for Amphora as a Contraceptive
Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora
Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch
Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study
Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla
Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion
Jun 26, 2014: Evofem Announces the Completion of the Largest Phase III Contraceptive Clinical Trial to Date
Jun 20, 2014: Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion Transdermal Delivery Device
Jul 24, 2013: Health Decisions Completes Enrollment of Evofem's 3,400-subject Global Trial of Amphora® Non-hormonal Contraceptive Gel
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Contraception, H2 2015
Number of Products under Development for Contraception - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Contraception - Pipeline by Agile Therapeutics, Inc., H2 2015
Contraception - Pipeline by Allergan Plc, H2 2015
Contraception - Pipeline by ANI Pharmaceuticals, Inc., H2 2015
Contraception - Pipeline by Antares Pharma, Inc., H2 2015
Contraception - Pipeline by Evofem, Inc., H2 2015
Contraception - Pipeline by Hydra Biosciences, Inc., H2 2015
Contraception - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Contraception - Pipeline by Orbis Biosciences, Inc., H2 2015
Contraception - Pipeline by Pantarhei Bioscience BV, H2 2015
Contraception - Pipeline by Spermatech AS, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Contraception Therapeutics - Recent Pipeline Updates, H2 2015
Contraception - Dormant Projects, H2 2015
Contraception - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Contraception, H2 2015
Number of Products under Development for Contraception - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report